Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights

Introduction

Mycoplasma pneumoniae (MP) is a leading cause of respiratory tract infections in children, accounting for approximately 10–40% of community-acquired pneumonia (CAP) cases in pediatric populations.¹ Unlike bacteria with cell walls, MP lacks a peptidoglycan structure, rendering it inherently resistant to β-lactam antibiotics, such as penicillins and cephalosporins.² The pathogen is primarily transmitted through respiratory droplets, with seasonal variations in different geographical regions.³ In northern China, MP infections are more prevalent during winter and spring, whereas in southern China, cases peak in summer and autumn.⁴ Macrolide antibiotics, including azithromycin and erythromycin, are the first-line treatment for MP pneumonia (MPP) in children, given their efficacy and safety profile.⁵ However, widespread macrolide resistance (MRMP) has emerged as a significant challenge, particularly in Asia, where resistance rates have exceeded 80% in some regions.⁶ The increasing prevalence of macrolide-resistant strains has led to a rise in severe and refractory cases, complicating the clinical management of the disease.

Refractory Mycoplasma pneumoniae pneumonia (RMPP) represents a severe and persistent form of MPP, characterized by prolonged fever lasting ≥7 days despite macrolide therapy, progressive lung involvement, and potential extrapulmonary complications.⁷ The diagnostic criteria for RMPP were first proposed by Japanese researchers in 2008 and have since been widely adopted in clinical practice.⁷ Especially, RMPP is diagnosed based on three primary criteria: persistent fever despite appropriate macrolide therapy for at least 7 days, progressive radiographic deterioration, including lung consolidation and pleural effusion, and extrapulmonary complications such as encephalitis, myocarditis, hemolytic anemia, or thrombosis.⁸ The condition is more frequently observed in older children (≥5 years old), who tend to exhibit a stronger immune response, often leading to excessive inflammatory activation and more severe lung injury.⁹

The clinical management of RMPP poses significant challenges due to its complex pathophysiology and limited effective treatment options. Antibiotic resistance remains a major concern, as the increasing prevalence of MRMP strains significantly reduces the efficacy of macrolide therapy.⁶ Furthermore, excessive immune activation, characterized by Th1/Th2 imbalance and cytokine overproduction, exacerbates lung damage and contributes to systemic complications.¹⁰ Mucus hypersecretion and airway obstruction are common in severe cases, leading to atelectasis and impaired pulmonary function.¹¹ Additionally, hypercoagulability and vascular endothelial dysfunction have been observed in RMPP, increasing the risk of thromboembolic events.¹² While alternative antibiotics such as tetracyclines and fluoroquinolones have been considered for treatment, their use in young children is limited due to concerns regarding their effects on bone and cartilage development.¹³ Immunomodulatory therapies, including corticosteroids and intravenous immunoglobulin (IVIG), are commonly used in severe cases, but their optimal dosing strategies and long-term safety remain subjects of ongoing debate.¹⁴

Given these challenges, there has been growing interest in complementary and alternative therapeutic approaches, particularly Traditional Chinese Medicine (TCM). In recent years, TCM has been explored for its potential to inhibit MP proliferation, modulate immune responses, reduce inflammation, improve microcirculation, and alleviate adverse effects associated with conventional therapies.¹⁵ Several studies suggest that integrating TCM with standard antibiotic and immunomodulatory therapies may offer a more individualized and comprehensive approach to managing RMPP, improving clinical outcomes in affected children.^15,16 Therefore, this review summarizes the mechanisms underlying RMPP and critically evaluates the potential role of traditional Chinese medicine as an adjunctive therapeutic strategy in pediatric management.

Pathogenesis of RMPP

The exact pathogenesis of RMPP remains incompletely understood, but it is believed to involve a combination of macrolide resistance, abnormal immune responses, excessive mucus production, hypercoagulability, and co-infections (Table 1). These factors contribute to the disease’s severity and treatment challenges.

Table 1 Comprehensive Summary of the Pathogenesis, Clinical Manifestations, and Treatment Strategies of Refractory Mycoplasma Pneumoniae Pneumonia (RMPP)

Antibiotic Resistance Mechanisms

MP lacks a cell wall, making it naturally resistant to β-lactam antibiotics.¹⁷ Macrolides target the bacterial 50S ribosomal subunit, inhibiting protein synthesis.¹⁸ However, point mutations in the 23S rRNA gene at positions A2063G, A2064G, and A2067G significantly reduce the binding affinity of macrolides, leading to resistance.¹⁹ Long-term and widespread use of macrolides has driven the selection of resistant MP strains, with resistance rates in Asia exceeding 80%.²⁰ In macrolide-resistant cases, persistent bacterial replication and colonization prolong the inflammatory process, contributing to disease progression and refractory symptoms.²¹ Additionally, studies have suggested that alterations in MP membrane lipid metabolism and transporter proteins may play a role in antibiotic resistance.²² Dysregulation in these pathways enhances the bacterium’s ability to evade host immune responses and therapeutic interventions.²²

Abnormal Immune Responses

In addition to antibiotic resistance, excessive immune activation and dysregulated inflammatory responses play a crucial role in the pathogenesis of RMPP.²³ Unlike typical MPP cases, where inflammation is primarily controlled by the host immune system, RMPP exhibits aberrant immune responses that contribute to lung injury and systemic complications.²⁴

T-helper cell imbalance is a hallmark of RMPP.²⁵ Studies have shown that RMPP patients exhibit an excessive Th1/Th2 imbalance, with increased Th1-related cytokines (eg, IFN-γ, TNF-α) and Th2-related cytokines (eg, IL-4, IL-6, IL-18, IL-33).²⁶ The overproduction of IL-6 and TNF-α leads to a cytokine storm, which exacerbates lung inflammation and damages alveolar structures.²⁷ Additionally, IL-18 activation stimulates macrophages and natural killer (NK) cells, further promoting the release of pro-inflammatory cytokines.²⁸ IL-33, a key mediator of Th2-driven immunity, enhances eosinophilic inflammation and mucus secretion, contributing to airway obstruction.²⁹

Extrapulmonary complications in RMPP are partly attributed to immune complex deposition in multiple organs, including the heart, kidneys, and central nervous system.³⁰ MP shares structural antigens with host tissues, leading to autoimmune reactions that can trigger myocarditis, encephalitis, and hemolytic anemia.³¹ These immune mechanisms justify the clinical use of corticosteroids and intravenous immunoglobulin (IVIG) for severe pediatric RMPP.

Airway Mucus Plugging and Lung Injury

A distinctive feature of RMPP is excessive airway mucus production, which contributes to persistent cough, airway obstruction, and worsening respiratory distress.³² The accumulation of thick mucus plugs in the bronchi leads to atelectasis and ventilation impairment, further complicating treatment.³³

The overproduction of mucus is driven by elevated levels of IL-6 and IL-8, which stimulate goblet cell hyperplasia and excessive mucus secretion.³⁴ Inflammatory damage to ciliary epithelial cells impairs mucociliary clearance, allowing mucus to accumulate and form airway plugs.³² Chest imaging in RMPP often reveals lung consolidation, atelectasis, and patchy infiltrates, indicative of mucus-related airway obstruction.³⁵

Severe mucus plugging also increases the risk of secondary bacterial infections, further complicating disease management.³⁶ The presence of thick, tenacious mucus creates an ideal environment for bacterial colonization, particularly with Streptococcus pneumoniae and Haemophilus influenzae.³⁷ Consequently, bronchoscopic mucus removal is sometimes required in severe cases to restore airway patency.³⁸ Clinically, early anti-inflammatory and airway-clearance strategies are critical to prevent mucus-associated complications.

Prothrombotic State and Microvascular Damage

Emerging evidence suggests that MP infection induces a hypercoagulable state, increasing the risk of thrombosis and vascular endothelial damage.³⁹ RMPP patients frequently exhibit elevated D-dimer levels, indicative of systemic hypercoagulability.⁴⁰ The exact mechanism remains unclear, but several factors contribute to this prothrombotic state.

First, MP infection triggers excessive immune activation, leading to vascular inflammation and endothelial dysfunction. The activation of complement pathways and neutrophil recruitment results in the release of pro-inflammatory cytokines, proteases, and reactive oxygen species (ROS), which disrupt vascular integrity.²³ Additionally, IL-6 and TNF-α promote platelet activation and fibrin deposition, further exacerbating coagulation abnormalities.⁴¹

Clinically, hypercoagulability in RMPP can manifest as pulmonary embolism, cerebral infarction, and deep vein thrombosis.³⁹ Anticoagulation therapy with low-molecular-weight heparin (LMWH) has been used in severe cases, but there is no standardized protocol for its use in pediatric patients.⁴²

Co-Infections and Disease Exacerbation

MP infection compromises airway defenses, predisposing patients to bacterial and viral co-infections that can worsen disease severity.²¹ Bacterial co-infections, particularly with Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus, are commonly observed in severe RMPP cases.⁴³ These secondary infections contribute to persistent fever, worsening lung consolidation, and prolonged hospitalization.³⁵

Viral co-infections are also common in children with RMPP, with human bocavirus (HBoV), respiratory syncytial virus (RSV), and rhinovirus (HRV) being frequently detected.⁴³ Viral infections exacerbate airway inflammation and immune dysregulation, leading to greater disease severity and prolonged recovery times.³²

Given the multifactorial nature of RMPP pathogenesis, a comprehensive treatment strategy targeting both infection control and immune modulation is essential. The following sections will discuss conventional treatment approaches, their limitations, and the potential role of Traditional Chinese Medicine (TCM) in addressing these challenges.

Conventional Treatment Approaches and Challenges

Antibiotic Therapy

Macrolides, including azithromycin, clarithromycin, and erythromycin, are the first-line treatment for MPP.¹³ These antibiotics exert their antibacterial effects by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis.¹⁷ However, the increasing prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) has significantly reduced their efficacy, particularly in Asia, where resistance rates exceed 80%.⁴⁴ The emergence of macrolide resistance is largely attributed to point mutations in the 23S rRNA gene, which alter ribosomal structure and decrease macrolide binding affinity.⁴⁵ Consequently, persistent bacterial replication and prolonged immune activation contribute to the development of RMPP.

For macrolide-resistant cases, alternative antibiotics such as tetracyclines (doxycycline, minocycline) and fluoroquinolones (moxifloxacin, levofloxacin) have been considered.¹³ These antibiotics target the 30S ribosomal subunit and DNA gyrase/topoisomerase IV, respectively, effectively inhibiting bacterial growth.¹⁸ However, their use in children is restricted due to safety concerns. Tetracyclines are generally contraindicated in children under eight years of age because they can lead to permanent tooth discoloration and impair bone growth.⁴⁶ Fluoroquinolones, although effective against resistant strains, are not recommended for children under eighteen years due to their association with cartilage damage and tendon rupture.⁴⁷

Given the limitations of monotherapy, some studies have explored the use of combination antibiotic therapy to improve treatment outcomes in RMPP. The combination of macrolides with tetracyclines or fluoroquinolones has been proposed as a strategy to enhance bacterial clearance.^48,49 However, there is no consensus on the optimal regimen, and concerns remain regarding potential antibiotic overuse, adverse effects, and further resistance development.

Immunomodulatory Therapy

Corticosteroids are frequently used in RMPP to reduce excessive inflammation, inhibit cytokine release, and prevent lung injury.⁵⁰ The optimal timing, dosage, and duration of corticosteroid therapy remain subjects of debate, but methylprednisolone pulse therapy is commonly adopted in severe cases. In moderate cases, low-dose regimens of 1–2 mg/kg/day for three to five days are typically administered. In severe cases with significant lung involvement, high-dose regimens of 10–30 mg/kg/day for three days, followed by gradual tapering, are often recommended.⁵¹

Corticosteroids have been shown to be effective in reducing fever duration, improving lung inflammation, and enhancing oxygenation.⁵² However, their use is associated with several potential adverse effects, including immune suppression, hyperglycemia, hypertension, and growth retardation in children.^53,54 Prolonged corticosteroid use may also lead to osteoporosis, gastrointestinal bleeding, and increased susceptibility to secondary infections.⁵⁵ Additionally, the timing of corticosteroid administration appears to influence treatment outcomes, with early intervention demonstrating greater effectiveness compared to delayed administration.⁵⁶

IVIG is occasionally used as an adjunct therapy in severe or steroid-resistant RMPP cases, particularly when autoimmune-mediated complications such as encephalitis, myocarditis, or hemolytic anemia are present.⁵⁷ IVIG functions by neutralizing pro-inflammatory cytokines, modulating immune responses, and preventing immune complex deposition in target organs.⁵⁸

Despite its potential benefits, IVIG therapy presents several limitations. The high cost of IVIG makes it less accessible in resource-limited settings, posing a financial barrier to widespread use.⁵⁹ There is currently a lack of standardized dosing guidelines, leading to variations in clinical practice.⁶⁰ Additionally, evidence supporting its efficacy remains limited, with some studies reporting no significant improvement in clinical outcomes.⁵⁷ Due to these concerns, IVIG is generally reserved for patients with severe systemic inflammation who do not respond to corticosteroid therapy.⁶¹

Antithrombotic Therapy

Emerging evidence suggests that MP infection induces a hypercoagulable state, leading to an increased risk of thrombosis and vascular endothelial injury.³⁹ Elevated D-dimer levels, fibrinogen concentration, and thrombin-antithrombin complex formation have been observed in RMPP patients, suggesting an abnormal coagulation profile.⁶² The underlying mechanisms remain unclear but are thought to involve excessive immune activation, endothelial dysfunction, and increased platelet aggregation.⁸

The most commonly reported thrombotic complications in RMPP include pulmonary embolism, cerebral infarction, and deep vein thrombosis.⁶³ These conditions can lead to significant morbidity, necessitating early recognition and intervention.⁶⁴ Anticoagulation therapy with low-molecular-weight heparin (LMWH) or vitamin K antagonists has been used in severe cases to prevent clot formation and reduce the risk of embolic events.⁶⁵ However, the use of anticoagulation in pediatric RMPP patients remains controversial due to the absence of standardized guidelines and the risk of bleeding complications.

Although early identification of thrombotic complications is crucial, routine anticoagulation therapy is not recommended for all RMPP patients.⁶⁶ Instead, D-dimer monitoring and coagulation assessments should be performed in high-risk patients to guide individualized treatment strategies.⁶⁷

Limitations of Conventional Therapies

Despite advancements in antibiotic therapy, immunomodulation, and anticoagulation, significant challenges remain in the management of RMPP. The increasing prevalence of macrolide-resistant strains has reduced the effectiveness of first-line antibiotics, limiting treatment options. Alternative antibiotics such as tetracyclines and fluoroquinolones are effective but have age-related safety concerns that restrict their use in children. Immunomodulatory therapies, including corticosteroids and IVIG, can ameliorate excessive inflammation, but their optimal dosing strategies and long-term safety profiles remain unclear. Additionally, the lack of standardized anticoagulation guidelines complicates the management of RMPP-related thrombotic complications.

Given these challenges, there is growing interest in complementary and integrative approaches, particularly TCM. TCM has been explored for its potential to inhibit MP replication, regulate immune responses, reduce inflammatory damage, and improve microcirculation.⁴¹ The following section will discuss TCM approaches and their role in addressing the limitations of conventional treatments.

Traditional Chinese Medicine (TCM) in the Management of RMPP

TCM Perspective on RMPP

In TCM, RMPP in children is classified under “pneumonia with dyspneic cough”, characterized by labored breathing, persistent cough, and fever.¹⁵ TCM interprets this condition as one of “root deficiency and branch excess”.⁶⁸ The “root” refers to internal deficiencies—particularly Qi deficiency (a weakness of vital energy, commonly in the lungs and spleen) and Yin deficiency (depletion of fluids due to prolonged fever)—that reduce the body’s resistance. The “branch”, by contrast, represents excessive pathogenic factors such as phlegm-heat, toxic heat, and blood stasis, which accumulate during infection. Persistent high fever and inflammation correspond to “heat toxin”, excessive mucus congestion indicates “phlegm obstruction”, and vascular injury or microthrombosis corresponds to “blood stasis”. This conceptual framework mirrors the biomedical view of RMPP as a condition involving persistent infection, immune overactivation, mucus plugging, and vascular injury in a host with reduced immunologic resilience.

Based on these principles, TCM treatment aims to both eliminate the pathogenic excess and reinforce the body’s deficiency. The key therapeutic principles included clearing heat and resolving toxin to suppress excessive inflammation, transforming phlegm and opening the lung to improve ventilation and sputum clearance, invigorating blood circulation and removing stasis to enhance microcirculation and reduce consolidation, and tonifying Qi and nourishing Yin to strengthen recovery and prevent relapse.⁶⁹ This stage-based approach adapts dynamically to disease progression: in the acute febrile phase, “heat-clearing and toxin-resolving” formulas predominate, while in the recovery phase, Qi- and Yin-tonifying herbs are introduced to restore physiological balance.

Mechanisms of TCM in Treating RMPP

Multi-Target and Multi-Pathway Mechanisms

Modern research increasingly reveals that TCM exerts its therapeutic effects on RMPP through a multi-component, multi-target, and multi-pathway approach.⁷⁰ Unlike single-compound pharmaceuticals, TCM formulas consist of numerous bioactive constituents—flavonoids, alkaloids, terpenoids, and saponins—that act synergistically to modulate inflammation, immunity, microbial proliferation, and tissue repair.⁷¹ Network pharmacology and metabolomic analyses have shown that many TCM formulations target critical molecular pathways such as NF-κB, NLRP3 inflammasome, AMPK/mTOR, and MAPK, thereby reducing hyperinflammation, oxidative stress, and immune overactivation associated with RMPP pathogenesis.⁷²

Anti-Mycoplasma and Antimicrobial Activity

Several TCM herbs have demonstrated direct anti-Mycoplasma effects or synergy with antibiotics. Scutellaria baicalensis (Huangqin) contains baicalin and baicalein, which suppress M. pneumoniae growth and inhibit bacterial adherence.⁷³ Isatis indigotica (Banlangen) and Houttuynia cordata (Yuxingcao) exhibit broad-spectrum antimicrobial and antiviral effects by disrupting microbial nucleic acid synthesis and enhancing macrophage phagocytosis.⁷⁴ These actions not only reduce microbial load but also enhance the effectiveness of macrolide antibiotics—critical in RMPP cases that are often resistant to conventional therapy.

Anti-Inflammatory and Immunomodulatory Effects

One hallmark of RMPP is excessive immune activation leading to lung tissue damage.⁷⁵ TCM formulas rich in polyphenols and saponins modulate both innate and adaptive immune responses. For instance, Forsythia suspensa (Lianqiao) and Scutellaria baicalensis (Huangqin) downregulate pro-inflammatory cytokines (TNF-α, IL-6, IL-8) by suppressing the NF-κB and MAPK pathways.⁷⁶ Glycyrrhiza uralensis (Gancao) reduces HMGB1-mediated inflammation,⁷⁷ while Astragalus membranaceus (Huangqi) and Cordyceps sinensis promote immune homeostasis by enhancing CD4⁺ T-cell function and balancing Th1/Th2 responses.^78,79 Clinical trials in recent years have shown that integrating TCM formulas with standard antibiotic therapy significantly lowers serum CRP, IL-6, and TNF-α, shortening fever duration and accelerating radiographic resolution.⁸⁰

Bronchodilation and Mucus Clearance

Airway obstruction caused by mucus hypersecretion is a major contributor to respiratory distress in RMPP.⁸¹ Herbs such as Ephedra sinica (Mahuang) and Armeniacae Semen (Xingren) —components of the classical Ma Xing Shi Gan Tang (Maxing Shigan Decoction)—exert bronchodilatory and antitussive effects.⁸² Ephedrine relaxes bronchial smooth muscle via β₂-adrenergic stimulation, while amygdalin from Xingren suppresses cough reflex and aids expectoration.⁸³ Platycodon grandiflorus (Jiegeng) promotes mucus clearance by increasing ciliary motility and reducing sputum viscosity.⁸⁴ These properties collectively alleviate wheezing and dyspnea, improving pulmonary ventilation and oxygenation in pediatric patients.

Protection and Repair of Lung Tissue

Beyond antimicrobial and anti-inflammatory actions, TCM herbs also protect alveolar epithelium and promote tissue repair.⁸⁵ Salvia miltiorrhiza (Danshen) and Panax notoginseng (Sanqi) enhance microcirculatory perfusion, inhibit platelet aggregation, and mitigate endothelial injury—mechanistically preventing microthrombosis often observed in RMPP.⁸⁶ Danshen’s tanshinones exhibit potent antioxidative activity, reducing lipid peroxidation and improving alveolar-capillary integrity.⁸⁷ Experimental models confirm that these herbs downregulate TGF-β1 and α-SMA expression, mitigating pulmonary fibrosis and aiding recovery.⁸⁸

Regulation of Cell Death and Autophagy

Recent molecular studies have uncovered that certain TCM formulations modulate inflammatory cell death pathways. For instance, Maxing Shigan Decoction inhibits NLRP3 inflammasome activation and pyroptosis in alveolar macrophages by promoting autophagy via the AMPK/mTOR/ULK1 signaling axis.⁸⁹ This not only reduces IL-1β secretion but also prevents excessive cell death and lung injury.⁹⁰ Such mechanistic discoveries bridge traditional TCM theory—“clearing heat and toxin”—with modern immunopathological understanding.

Reduction of Therapy-Related Side Effects

Another notable advantage of TCM integration is its ability to mitigate the adverse effects of antibiotics and corticosteroids. Glycyrrhiza uralensis protects gastric mucosa and supports adrenal function, while Qi-tonifying herbs like Astragalus and Codonopsis pilosula (Dangshen) improve appetite, enhance vitality, and restore gut microbiota balance after prolonged drug therapy.⁹¹ This holistic support helps maintain immune resilience and promotes full convalescence.

Integrative Clinical Evidence

Recent clinical and experimental studies provide tangible evidence supporting these mechanisms. For instance, Ling et al¹⁵ reported that children receiving “heat-phlegm and toxin-clearing” TCM therapy experienced faster fever resolution and improved chest imaging outcomes compared with controls. Formulas incorporating Forsythia, Scutellaria, and Houttuynia significantly decreased inflammatory cytokines and sputum production,⁹² while “blood-activating” herbs like Salvia accelerated the absorption of pulmonary infiltrates.⁹³ Collectively, these findings confirm that TCM not only alleviates symptoms but also modulates the immune–inflammatory cascade and promotes tissue repair.

Commonly Used Formulas, Clinical Applications, and Evidence for Efficacy and Safety

Recently, a growing body of clinical evidence from China has evaluated TCM herbal formulas as adjunctive therapies in pediatric RMPP.¹⁵ These studies consistently report that the combination of TCM and conventional Western therapy accelerates symptom resolution, improves radiological recovery, and reduces inflammatory biomarkers without increasing adverse events. The main outcome indicators assessed include time to fever clearance, cough duration, lung auscultation findings, chest imaging absorption, and length of hospitalization. Below, major formulas used in RMPP are summarized, highlighting their composition, TCM indications, mechanisms, and supporting evidence (Table 2).

Table 2 Summary of Commonly Used TCM Formulas for Refractory Mycoplasma Pneumoniae Pneumonia (RMPP)

Ma Xing Shi Gan Tang (Maxingshigan Decoction)

This classical prescription—comprising Ephedra sinica (Ma Huang), Armeniacae Semen (Xing Ren), Gypsum fibrosum (Shi Gao), and Glycyrrhiza uralensis (Gan Cao)—is traditionally used for “lung heat with wheezing”, typified by high fever, cough, and labored breathing.⁹⁴ In the context of RMPP, it corresponds to “heat obstructing the lungs”, where excessive inflammation and thick phlegm hinder normal respiration.⁹⁵

Numerous RCTs and meta-analyses support its effectiveness. A meta-analysis of 13 RCTs (657 patients) reported that adding Maxing Shigan-based prescriptions to antibiotics increased clinical efficacy (pooled OR ≈ 2.3) compared with antibiotics alone.⁹⁶ A larger 2025 systematic review involving 6682 patients with community-acquired pneumonia found that combined therapy shortened fever, cough, sputum, and dyspnea durations by 1.6–2.4 days.⁹⁷ In pediatric RMPP specifically, integrated therapy achieved faster resolution of fever and rales (~2–3 days earlier) and enhanced chest X-ray absorption by ~2.7 days on average.^98,99

Pharmacological studies confirm that Maxing Shigan Decoction suppresses excessive lung inflammation by inhibiting NLRP3 inflammasome activation and promoting autophagy through the AMPK/mTOR/ULK1 pathway.⁸⁹ Clinically, it reduces IL-6 and TNF-α levels, consistent with its heat-clearing, antipyretic effects.⁹⁰ Safety data are reassuring: pooled analyses show no significant difference in adverse event rates between herbal and control groups (3.6% vs. 5.4%), with only mild gastrointestinal discomfort occasionally reported.⁹⁷ When properly dosed, the formula is well-tolerated in children.⁹⁷

Qingfei Paidu Decoction (QFPD)

Qingfei Paidu Decoction, formulated during the COVID-19 pandemic, is a composite of classical recipes such as Ma Xing Shi Gan Tang, Shegan Mahuang Tang, Xiao Chaihu Tang, and Wuling San.¹⁰⁰ It contains over 20 herbs, including Ephedra, Gypsum, Apricot kernel, Licorice, Bupleurum, Scutellaria, Pinellia, and Atractylodes.¹⁰¹ It “clears heat and detoxifies the lung”, “resolves dampness”, and “supports the spleen.¹⁰²“ Clinically, it is used in severe RMPP with persistent high fever, radiographic consolidation, and respiratory distress.

Although pediatric RMPP-specific RCTs remain limited, QFPD’s efficacy is inferred from its success in severe viral pneumonias. Studies during COVID-19 demonstrated that QFPD reduced disease severity, inflammation, and hospital stay without major adverse effects.¹⁰³ Experimental research revealed that QFPD suppresses hyperinflammation by downregulating TNF-α, IL-6, and complement C3 activation while modulating the HIF-1α/NF-κB axis.¹⁰⁴ These actions reduce pulmonary edema, inhibit cytokine storms, and improve tissue oxygenation.¹⁰⁵ Its “broad-spectrum” mechanism—combining antiviral, anti-inflammatory, and organ-protective effects—makes it a rational choice for integrative RMPP therapy.

Clinical use in both adults and children during the COVID-19 pandemic showed excellent tolerability. Mild gastrointestinal reactions and transient rashes were occasionally observed but self-resolved.¹⁰¹ Given the inclusion of Ephedra, caution is warranted in young children; however, its stimulating effects are balanced by Gypsum and dampness-clearing herbs.¹⁰⁶ Physicians generally restrict QFPD to short-term use during acute illness, switching to milder tonics during recovery.¹⁰⁷

Lianhua Qingwen (LHQW) Capsules/Granules

LHQW is a patented modern TCM formula combining Forsythia suspensa, Lonicera japonica, Ephedra, Gypsum, Isatis root, Houttuynia cordata, Rheum palmatum, and others.¹⁰⁸ It “clears heat and detoxifies, disperses lung obstruction, and releases the exterior”, addressing wind-heat toxin syndromes with fever, sore throat, and productive cough.¹⁰⁸

A 2024 meta-analysis (Li et al) encompassing 15 RCTs and 1909 pediatric Mycoplasma pneumoniae cases found that LHQW plus azithromycin significantly improved outcomes versus azithromycin alone—higher response rate (RR = 1.17), faster fever relief (by ~1.3 days), cough resolution (by ~1.7 days), and earlier rales disappearance (by ~1.5 days).¹⁰⁹ Inflammatory biomarkers (CRP, PCT, IL-6, TNF-α) were markedly reduced, and pulmonary function (FEV₁, FVC) improved.^109,110

Pharmacological studies confirm that LHQW inhibits NF-κB and NLRP3 inflammasome activation, suppressing IL-1β, IL-6, and TNF-α release.¹¹¹ It also enhances mucosal barrier function, reduces oxidative stress via Forsythia and Rhodiola constituents, and impedes pathogen adhesion.¹¹² These multifaceted mechanisms explain its broad efficacy in respiratory infections including RMPP.

Across trials, LHQW showed a favorable safety profile—adverse event incidence was lower in the herbal combination group (RR = 0.65).¹⁰⁹ Mild digestive disturbances or transient rash were rare and self-limiting. Given its standardized granule form and wide pediatric use, LHQW is considered a safe and practical adjunct for RMPP management.

Other Formulas and Interventions

The shuanghuanglian (SHL) preparations were composed of Lonicera, Forsythia, and Scutellaria, SHL syrups and injections are classic “heat-toxin clearing” remedies.¹¹³ A 2021 meta-analysis of 27 RCTs (2884 children) reported improved cure rates (RR ≈ 1.14) and shortened fever (by 1.7 days), cough (by 3 days), and rales (by 2.1 days) durations in Mycoplasma pneumonia.¹¹⁴ SHL also improved T-cell subset balance and reduced IL-6 and TNF-α levels, with no severe adverse effects noted.¹¹⁵

The second one is Yin-Nourishing and Lung-Tonifying Formulas. During the convalescent phase of RMPP, when children exhibit lung Yin or Qi deficiency (dry cough, fatigue), formulas such as Sha Shen Mai Dong Tang and Bu Fei Tang are employed.¹¹⁶ These prescriptions, containing Glehnia, Ophiopogon, Astragalus, and Codonopsis, restore lung moisture, strengthen immunity, and prevent relapse.¹¹⁷ They are mild, well-tolerated, and often used as follow-up therapy after heat-clearing formulas.

In addition, intravenous herbal preparations. In severe or ICU cases, injectable formulations like Xiyanping (andrographolide), Tanreqing, and Reduning are used alongside antibiotics.^118–120 These agents exert rapid anti-inflammatory and antiviral actions and have shown improved symptom resolution without increased toxicity in pediatric MPP. Although vigilance for allergic reactions is necessary, large-scale reviews report low adverse event rates.^121,122

Collectively, clinical data in recent years demonstrate that integrating TCM formulas with Western medicine improves the therapeutic response in RMPP. Children treated with herbal adjuncts experience faster symptom relief, quicker radiographic recovery, and improved inflammatory profiles without elevated risk of adverse events. Meta-analyses indicate comparable or lower side effect rates relative to standard therapy. No major herb-drug interactions have been documented. Thus, when prescribed based on syndrome differentiation and under appropriate supervision, TCM represents a safe and effective complementary approach for pediatric RMPP management.

Integration of TCM with Western Medicine

Combination with Antibiotics

TCM does not replace antibiotics but complements them through anti-mycoplasmal, anti-inflammatory, and immunoregulatory actions. Meta-analytic evidence shows that adding TCM to azithromycin more than doubles the cure rate (OR≈2.34) and markedly increases overall effectiveness (OR≈5.21), while shortening fever and cough durations by ~1.6 days each and accelerating resolution of lung rales by ~1.1 days.¹²³ These clinical gains are paralleled by larger reductions in CRP, IL-6, and TNF-α, indicating better inflammatory control. Notably, adverse reactions are fewer with the combination (OR≈0.37), suggesting that certain herbs may protect the gut–liver axis and attenuate drug-related discomfort.¹²³ Mechanistically, herbs such as Houttuynia and Scutellaria may suppress M. pneumoniae growth or virulence and target host pathways (eg, NF-κB, NLRP3), yielding a more comprehensive therapeutic profile than antibiotics alone and decreasing the need for second-line agents or ventilatory support.^124,125

Steroid-Sparing Effects

Because corticosteroids are often required to quell hyperinflammation in RMPP, strategies that reduce steroid dose or duration are clinically valuable.¹²⁶ TCM formulas provide overlapping anti-cytokine effects (eg, lowering IL-6 and TNF-α) and promote airway mucus clearance, which together can stabilize clinical status earlier and lower the threshold for steroid initiation or allow faster tapering once started.¹²³ Evidence from other severe respiratory conditions (eg, SARS) suggests integrated regimens can lower daily steroid dose without compromising recovery, supporting the biological plausibility of a steroid-sparing effect in RMPP pending direct confirmation.¹²⁷ By decreasing steroid dependence, integrative protocols may help avoid hyperglycemia, mood changes, infections, and growth suppression associated with prolonged corticosteroid use in children.^54,128

Use Alongside IVIG and Other Immunomodulators

IVIG remains reserved for severe, immune-mediated RMPP (eg, encephalitis, myocarditis, severe hemolysis).¹²⁹ Although pediatric RMPP-specific trials of “TCM+IVIG” are limited, clinical experience indicates that TCM can be safely co-administered to support microcirculation, reduce vascular inflammation, and enhance recovery after IVIG.^130,131 While direct trials in children with RMPP treated with IVIG plus blood-activating herbs (such as Salvia miltiorrhiza) or nutritive-level formulations (such as Rehmannia-based combinations) are limited, pharmacological data and adult/animal studies suggest a theoretical benefit in improving microcirculation and reducing vascular inflammation. This provides a rationale for their adjunctive use alongside IVIG, particularly in complex cases involving neurologic or vascular complications.^132,133

Safety, Interactions, and Practical Protocol

When prescribed by weight and stage, pediatric safety of integrative therapy is favorable, with overall adverse-event rates comparable to—or lower than—antibiotics alone. Potential herb–drug interactions are manageable with routine monitoring: Glycyrrhiza (licorice) can potentiate corticosteroid effects (via 11β-HSD2 inhibition) and warrants awareness;¹³⁴ Ephedra may add adrenergic effects with β-agonists but is typically used at low pediatric doses;¹³⁵ and minor pharmacokinetic shifts (eg, with Scutellaria) have not translated into clinical harm.¹³⁶ A pragmatic protocol is to (i) initiate azithromycin plus a heat-clearing TCM formula (eg, Maxing Shigan Tang or Lianhua Qingwen) at diagnosis; (ii) if RMPP criteria persist at day 5–7, add corticosteroids and broaden TCM to formulas such as Qingfei Paidu Decoction, consider bronchoscopy for mucus plugs, and adjust antibiotics if MRMP is suspected; (iii) in complications, use IVIG and targeted Western measures with TCM support; and (iv) during recovery, transition to Qi-/Yin-tonifying formulas (eg, Bu Fei Tang, Sha Shen Mai Dong Tang) to consolidate gains and reduce relapse. This time-sequenced, mechanism-informed integration leverages complementary strengths—pathogen eradication, immune recalibration, mucus and microvascular management, and host reconditioning—to shorten disease course, improve radiographic and laboratory endpoints, and maintain a strong safety profile in children with RMPP.

Future Directions

The management of RMPP remains a significant challenge due to the increasing prevalence of MRMP and the complexity of immune-mediated lung injury.^6,137 While conventional therapies, including antibiotics, corticosteroids, and immunomodulatory agents, are essential for treatment, their limitations highlight the need for complementary approaches. TCM has shown promise in modulating immune responses, reducing inflammation, improving microcirculation, and alleviating disease severity. Moving forward, a comprehensive approach integrating TCM with modern medical therapies may optimize patient outcomes and reduce complications associated with RMPP.

Given the multi-factorial pathogenesis of RMPP, the integration of TCM with conventional treatments has the potential to enhance therapeutic efficacy. TCM formulations, when combined with antibiotics, may reduce disease duration, enhance bacterial clearance, and mitigate excessive inflammatory responses.⁷¹ Furthermore, TCM’s immune-regulating and anti-inflammatory properties could decrease reliance on corticosteroids, thereby minimizing the risk of steroid-related complications.¹³⁸

Personalized TCM treatment based on syndrome differentiation is a key advantage, as it allows for individualized therapeutic approaches that address different disease phases and patient-specific pathophysiology.¹³⁹ This precision-based strategy aligns with modern medical principles of personalized medicine. Additionally, multi-target therapy using bioactive TCM compounds provides a unique advantage over single-target drugs by concurrently addressing infection control, immune modulation, and microvascular protection.¹⁵ Future studies should explore the synergy between TCM and conventional treatments to establish evidence-based integrated protocols for RMPP management.

Despite the growing recognition of TCM in RMPP treatment, several research gaps need to be addressed. Standardization of TCM treatment protocols remains a critical challenge, as variations in herbal formulations, dosages, and administration methods can impact clinical outcomes.¹⁴⁰ Establishing consensus guidelines based on rigorous clinical evidence is essential to promote the widespread adoption of TCM in RMPP treatment.

Furthermore, well-designed, large-scale randomized controlled trials (RCTs) are needed to validate the efficacy, safety, and long-term benefits of TCM in RMPP management. These trials should focus on evaluating the therapeutic effects of TCM alone and in combination with standard treatments, comparing clinical endpoints such as symptom resolution, lung function recovery, and recurrence rates.

On a mechanistic level, exploring the molecular and immunological pathways influenced by TCM could enhance our understanding of its therapeutic potential. Investigating how TCM modulates cytokine networks, regulates immune homeostasis, and impacts the pulmonary microbiome may provide insights into novel treatment targets for RMPP. Integrating systems pharmacology, network analysis, and multi-omics technologies could further elucidate the bioactive components and pharmacokinetics of key herbal medicines used in RMPP treatment.

Conclusion

RMPP remains a complex and challenging condition due to antibiotic resistance, dysregulated immune responses, and persistent inflammation. Conventional therapies, while effective, have notable limitations, necessitating complementary treatment strategies. TCM offers a promising adjunctive approach by targeting infection control, immune modulation, inflammation resolution, and coagulation balance, which are critical aspects of RMPP pathogenesis.

Moving forward, a multidisciplinary approach integrating TCM with modern medicine may improve clinical outcomes in pediatric RMPP patients. Future research should focus on optimizing integrated treatment protocols, conducting high-quality clinical trials, and elucidating the mechanistic basis of TCM therapies. With further advancements in evidence-based research and standardization, TCM has the potential to become an integral part of comprehensive RMPP management, contributing to more effective and personalized therapeutic strategies.